The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NIHR Journals Library
2004-03-01
|
| Series: | Health Technology Assessment |
| Online Access: | https://doi.org/10.3310/hta8110 |
| _version_ | 1819073624030576640 |
|---|---|
| author | P Barton P Jobanputra J Wilson S Bryan A Burls |
| author_facet | P Barton P Jobanputra J Wilson S Bryan A Burls |
| author_sort | P Barton |
| collection | DOAJ |
| first_indexed | 2024-12-21T17:56:34Z |
| format | Article |
| id | doaj.art-c9d602e1849c4b419c7e44389833dba2 |
| institution | Directory Open Access Journal |
| issn | 1366-5278 |
| language | English |
| last_indexed | 2024-12-21T17:56:34Z |
| publishDate | 2004-03-01 |
| publisher | NIHR Journals Library |
| record_format | Article |
| series | Health Technology Assessment |
| spelling | doaj.art-c9d602e1849c4b419c7e44389833dba22022-12-21T18:55:12ZengNIHR Journals LibraryHealth Technology Assessment1366-52782004-03-0181110.3310/hta8110The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritisP Barton0P JobanputraJ WilsonS BryanA BurlsHealth Services Management Centre, University of Birmingham, UKhttps://doi.org/10.3310/hta8110 |
| spellingShingle | P Barton P Jobanputra J Wilson S Bryan A Burls The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis Health Technology Assessment |
| title | The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| title_full | The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| title_fullStr | The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| title_full_unstemmed | The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| title_short | The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| title_sort | use of modelling to evaluate new drugs for patients with a chronic condition the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
| url | https://doi.org/10.3310/hta8110 |
| work_keys_str_mv | AT pbarton theuseofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT pjobanputra theuseofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT jwilson theuseofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT sbryan theuseofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT aburls theuseofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT pbarton useofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT pjobanputra useofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT jwilson useofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT sbryan useofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis AT aburls useofmodellingtoevaluatenewdrugsforpatientswithachronicconditionthecaseofantibodiesagainsttumournecrosisfactorinrheumatoidarthritis |